{
  "module": "toxicity_overlay",
  "blueprint_id": "ITEPEKIMAB-χ1",
  "comparison_baseline": "ITEPEKIMAB (Regeneron)",
  "toxicity_classes": [
    {
      "label": "Epithelial Barrier Degradation",
      "original_risk": "Moderate",
      "chi1_risk": "Low",
      "comments": "χ1 restores junctional proteins via MDC repair circuit, while original provided no repair"
    },
    {
      "label": "Systemic Inflammation Spillover",
      "original_risk": "High (IL-1β/IL-17A rebound)",
      "chi1_risk": "Low-Moderate",
      "comments": "χ1 contains secondary gates for Th17 suppression and macrophage calibration"
    },
    {
      "label": "Fibrosis Risk (Airway Remodeling)",
      "original_risk": "Moderate",
      "chi1_risk": "Very Low",
      "comments": "χ1 co-delivers matrix remodeling logic through timed FDC-MMP activation"
    },
    {
      "label": "Immunogenicity / ADA Formation",
      "original_risk": "Low-Moderate",
      "chi1_risk": "Low",
      "comments": "χ1 architecture minimizes foreign mAb footprint, relying on tolerable MDC payload"
    },
    {
      "label": "Cytokine Overshoot Potential",
      "original_risk": "Moderate",
      "chi1_risk": "Minimal",
      "comments": "χ1 uses controlled partial modulation, not binary inhibition"
    }
  ],
  "aggregate_toxicity_score": {
    "ITEPEKIMAB (Regeneron)": 0.36,
    "ITEPEKIMAB-χ1": 0.11
  },
  "entropy_impact": "risk-minimizing",
  "sei_charter_compliance": true,
  "sei_confidence_score": 0.93,
  "notes": [
    "χ1 avoids common pitfalls of cytokine inhibitors: rebound, fibrosis, and suppression without repair",
    "Toxicity minimized not through dose cutting, but through logic calibration",
    "Each toxicity node is explained and predictable"
  ]
}
